James Kochenderfer, MD

---

Authored Items

First-in-Human CAR T-Cell Trial Shows Activity in Multiple Myeloma

March 2016, Vol. 5, No. 2 - ASH 2015, ASH Highlights

CAR T-cell therapy has been striking in various hematologic malignancies, and, for the first time, the approach is being evaluated in multiple myeloma.At the meeting, James Kochenderfer, MD, of the Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, presented preliminary results from a phase [ Read More ]

CAR T-Cell Therapy Highly Active in Various Hematologic Malignancies

February 2016, Vol. 5, No. 1 - ASH 2015, ASH Highlights

CAR T cells demonstrated consistent activity in advanced hematologic malignancies evaluated in multiple small clinical trials reported at the meeting.Disease remission persisting for as long as 36 months occurred in 8 of the first 20 patients treated at the National Cancer Institute. The 40% overall response rate included 4 of [ Read More ]